Types of Articles (Original Article/Review Article /Case Studies)

this is the title of the article

First name **Last name**1, First name **Last name**2, First name **Last name**3\*

1. Affiliations of all contributing authors (Full address - Department, Institution’s State, and Country)

2. Affiliations of all contributing authors (Full address - Department, Institution’s State, and Country)

3. Affiliations of all contributing authors (Full address - Department, Institution’s State, and Country)

**Submission Date:** To be added by editorial staff during production

**Acceptance Date:** To be added by editorial staff during production

**Publication Date:** To be added by editorial staff during production

**\*Corresponding author:** Corresponding author name, email address, and phone number

**DOI**: To be added by editorial staff during production

IMRJ © 2025. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction, provided the original author and source are credited.

ABSTRACT

A summary of the research following a structured format which includes Introduction, Materials & Methods, Results, Discussions, and Conclusion. It should NOT exceed 250 words. It should NOT include citations or abbreviations. Include unique study identifier / URL where applicable (registration of study)

KEYWORDS:List 5 (five) keywords that describe the main topic of the manuscript

introduction

Provide a context or background for the study (i.e. the nature of the problem and its significance). State the specific purpose or research objective of, or hypothesis tested by, the study or observation.

materials and methods

Subsection

Materials & Methods should provide a detailed description of the materials, procedures, and analysis techniques used in the study. Ethical approval statement/s should be included when necessary. It should include only information that was available when the plan or protocol for the study was written; all information obtained during the study's conduct belongs in the Results section.

a) Subsubsection

Bulleted lists look like this:

* First bullet;
* Second bullet;
* Third bullet.

Numbered lists can be added as follows:

1. First item
2. Second item
3. Third item

b) Selection and description of participants

Describe your selection of the observational or experimental participants (patients or laboratory animals, including controls) clearly, including eligibility and exclusion criteria and a description of the source population. The guiding principle should be clarity about how and why a study was done in a particular way.

Technical information

Identify the methods, apparatus (give the manufacturer’s name and address in parentheses), and procedures in sufficient detail to allow other workers to reproduce the experiment. Give references to established methods, including statistical methods; provide references and brief descriptions for methods that have been published but are not well known; describe new or substantially modified methods; give reasons for using them; and evaluate their limitations. Identify precisely all drugs and chemicals used, including generic name(s), dose(s), and route(s) of administration. Authors submitting review manuscripts should include a section describing the methods used for locating, selecting, extracting, and synthesising data. These methods should also be summarised in the abstract.

Statistics

Describe statistical methods with enough detail to enable a knowledgeable reader with access to the original data to verify the reported results.

RESULTS

Present your results in logical sequence in the text, tables, and illustrations, giving the main or most important findings first. Do not repeat in the text all the data in the tables or illustrations; emphasise or summarise only important observations. When data are summarised in the Results section, give numeric results not only as derivatives (for example, percentages) but also as the absolute numbers from which the derivatives were calculated. Restrict tables and figures to those needed to explain the argument of the paper and to assess its support. Use graphs as an alternative to tables with many entries; do not duplicate data in graphs and tables.

All figures and tables must be referenced in the main text as Figure 1, Table 1



Figure 1. This is IMRJ logo(minimum resolution of 300 dpi ,jpeg)

**Table 1.** This is a table. This is a table. It should be positioned in the main text close to its first citation

|  |  |  |
| --- | --- | --- |
| Title 1 | Title 2 | Title 3 |
| entry 1 | Dataa | Datab |
| entry 2 | Datac | Data |

a Tables may have a footer.

b Tables may have a footer.

c Tables may have a footer.

 (a) (b)

**Figure 2**. This is a figure. If it contains multiple panels, they should be labelled as follows: (a) Description of the first panel; (b) Description of the second panel. Figures should be positioned in the main text close to their first citation.

discussion

The discussion section interprets key findings, comparing them with existing literature to highlight consistencies or discrepancies. It explains the significance of results, their theoretical or practical implications, and how they advance knowledge. Strengths and novel contributions are emphasized, while limitations, such as methodological constraints or biases, are acknowledged. Recommendations for future research address gaps and suggest methodological improvements. Finally, a concise conclusion reinforces the study's main contribution and real-world relevance without introducing new data or speculation.

conclusion

The conclusion summarizes the study’s key findings, emphasizing their significance and contributions to the field. It reinforces how the results address the research question, highlights practical or theoretical implications, and acknowledges any limitations. Finally, it suggests directions for future research while avoiding redundancy or new information.

*This section is optional but may be included if the manuscript reports patents resulting from the work.*

**Supplementary Materials:** Supporting information related to this study can be accessed at: www.imrj.com/x. This includes Figure S1: [Title], Table S1: [Title], and Video S1: [Title].

**Author Contributions:** Include a brief statement specifying the contribution of each author (e.g., research design, data analysis, critical manuscript writing and reviewing). Provide at minimum one significant contribution for each author according to ICMJE guidelines.

**Funding:** The funding statement should include the following: specific grant numbers, the full names of commercial companies that funded the study or authors, and whether any sponsors or funders (other than the named authors) played any role in the study design, data collection and analysis, decision to publish, and preparation of the manuscript. If they had no role in the research, include this sentence: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

**Institutional Review Board Statement:** If applicable, provide details on institutional ethics approval, including the review board’s name and approval number. If the study involved human subjects, state: “This research was conducted in compliance with the Declaration of Helsinki and approved by the Institutional Review Board (or Ethics Committee) of [Institution Name] (protocol number XXX, approved on [date]).” For animal studies, state: “The animal study protocol was approved by the Institutional Review Board (or Ethics Committee) of [Institution Name] (protocol number XXX, approved on [date]).” If ethical approval was waived, specify: “Ethical review was waived due to [reason].” If the study did not require ethical approval, indicate “Not applicable.” The Editorial Office may request additional information if necessary.

**Informed Consent Statement:** For studies involving human participants, include one of the following: “Informed consent was obtained from all participants,” or “Patient consent was waived due to [reason, with justification].” If the study does not involve human participants, state “Not applicable.” If identifiable patients are included, confirm that written consent for publication was obtained: “Written informed consent was received from the patient(s) for publication of this study.”

**Data Availability:** Mention whether the data supporting the findings is available and how it can be accessed

**Acknowledgements:** Individuals who contributed to the work but do not meet authorship criteria should be acknowledged in the Acknowledgments section, along with a description of their contributions. Authors are responsible for confirming that everyone named in the acknowledgments has agreed to be included. The author/s especially principal/corresponding author should identify the deserving authors based on the 4 criterias listed in the International Committee of Medical Journal Editors (ICMJE) guideline where the author of a manuscript is defined as someone who has provided (1) substantial contributions to the conception or design of the work or the acquisition, analysis, or interpretation of data for the work; AND (2) drafting the work or reviewing it critically for important intellectual content; AND (3) final approval of the version to be published; AND (4) agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Conflicts of Interest:** Declare any potential conflicts of interest related to the research or publication. If there are none then state “Authors have no conflict of interest to declare”

Citation

To be added by editorial staff during production.

references

1. Smith J, Brown K.The impact of climate change on vector-borne diseases. Lancet Infect Dis. 2023;23(5):456-63.

2. Johnson AB, Lee R, Martinez P, Wang T, Kim S, Patel H, et al. Advances in machine learning for epidemiology. J Med Inform. 2022;58(2):123-35.

3. Gordis L. Epidemiology. 6th ed. Philadelphia: Elsevier; 2019.

4. Thompson J. Predictive analytics in public health. In: Smith A, editor. Big data in healthcare. New York: Springer; 2021. p. 105-23.

5. Lee R, Wong T. AI-driven diagnostics for infectious diseases. Presented at: International Conference on AI in Medicine; 2021 Sep 15-18; London, UK.

6. Ali M. Machine learning models for disease prediction [dissertation]. Boston: Harvard University; 2020.

7. World Health Organization. Dengue and severe dengue [Internet]. Geneva: WHO; 2023 [cited 2024 Feb 5]. Available from: https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue

8. Institute of Medicine. The future of public health. Washington, DC: National Academies Press; 1988.

9. Centers for Disease Control and Prevention. Surveillance strategies for vector-borne diseases. Atlanta: CDC; 2022.

10. National Center for Health Statistics. COVID-19 mortality dataset [Internet]. Atlanta: CDC; 2022 [cited 2024 Feb 5]. Available from: https://www.cdc.gov/covid-data